Zimmer Biomet Inspection Finds Extensive GMP Woes

The document cites a range of issues that could tie to product safety, such as water and air quality, and maintenance of a sterile work environment. But the company says it is working with US FDA on its remediation plan and states that no known product safety issues are linked to the observations.

A 58-page, 14-observation FDA Form 483 issued after a recent US FDA inspection of Zimmer Biomet Holdings Inc. ’s Warsaw, Ind., plant is likely to lead to a warning letter and ongoing remediation efforts, one analysis states.

The firm issued a statement Dec. 14 acknowledging receiving the FDA-483 form. Analysts at Wells Fargo Securities obtained the form...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Regulation

More from Policy & Regulation